Haleon (LON:HLN) Shares Cross Below Two Hundred Day Moving Average – What’s Next?

Haleon plc (LON:HLN) shares crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of GBX 360.62 and traded as low as GBX 310.50. Haleon shares last traded at GBX 316.60, with a volume of 1,048,323,188 shares.

Haleon News Roundup

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon launched a £500 million share buyback, which should support earnings per share, return capital to investors and help fund employee share plans. Management also maintained its profit guidance. Haleon launches £500 million share buyback programme
• Neutral Sentiment: Third-quarter organic revenue increased 2.6%, while Haleon’s consumer-health portfolio continued to grow overall. However, the result was below management’s expectations, making the buyback appear more defensive than growth-driven. Haleon Q3 2026 trading update
• Negative Sentiment: Haleon reduced its fiscal 2026 organic revenue-growth forecast to approximately 2.5%, from a previous range of 3% to 5%. The downgrade reinforces investor concerns that sales momentum is slowing. Haleon trims 2026 growth outlook
• Negative Sentiment: Weaker-than-expected cough, cold and flu consumption reduced North American orders, while a raw-material classification change disrupted OTC-registered Centrum products in China. Haleon also expects a fourth-quarter revenue impact from accelerating a go-to-market change in Brazil. Haleon cuts revenue growth forecast

Analyst Upgrades and Downgrades

HLN has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered their target price on Haleon from GBX 335 to GBX 320 and set a “sell” rating for the company in a report on Wednesday, September 9th. Royal Bank Of Canada increased their price target on Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday, August 11th. Berenberg Bank raised their price objective on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 400 target price on shares of Haleon in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Haleon currently has an average rating of “Hold” and a consensus target price of GBX 387.80.

Haleon Trading Up 2.0%

The firm’s 50-day moving average is GBX 353.77 and its 200-day moving average is GBX 360.62. The company has a current ratio of 0.69, a quick ratio of 0.93 and a debt-to-equity ratio of 50.38. The firm has a market cap of £28.51 billion, a price-to-earnings ratio of 17.91, a P/E/G ratio of 1.49 and a beta of 0.24.

Haleon (LON:HLN) last released its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 earnings per share for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, sell-side analysts anticipate that Haleon plc will post 19.50 EPS for the current fiscal year.

Haleon declared that its Board of Directors has initiated a share repurchase plan on Thursday, October 29th that allows the company to repurchase £500 million in shares. This buyback authorization allows the company to repurchase up to 1.8% of its shares through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.